U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Neuroendocrine Tumor

MedGen UID:
1650213
•Concept ID:
C4743665
•
Neoplastic Process
Synonym: Advanced Well Differentiated Neuroendocrine Neoplasm

Definition

A neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.
Zhuo ZG, Zhu YK, Deng HY, Li G, Luo J, Alai GH, Lin YD
J BUON 2019 Jan-Feb;24(1):368-373. PMID: 30941993
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E, Karaca H, Koca S, Sevinç A, Hacioğlu B, Özkan M, Özçelik M, Duran AO, Hacibekiroğlu İ, Yildiz Y, Tanriverdi Ö, Menekşe S, Aksoy A, Bozkurt O, Urvay S, Uysal M, Demir H, Çiltaş A, Dane F
Anticancer Drugs 2017 Feb;28(2):222-229. doi: 10.1097/CAD.0000000000000445. PMID: 27768606
United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment.
Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ
World J Gastroenterol 2013 Apr 21;19(15):2348-54. doi: 10.3748/wjg.v19.i15.2348. PMID: 23613628Free PMC Article

Recent clinical studies

Therapy

Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases.
Lee FT, Williams J, Nordgren R, Schwarz JL, Setia N, Roggin K, Polite B, Rangrass G, Liao CY, Millis JM, Keutgen XM
Am J Surg 2024 Mar;229:17-23. Epub 2023 Sep 26 doi: 10.1016/j.amjsurg.2023.09.020. PMID: 37802701
Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.
Opalinska M, Lezaic L, Decristoforo C, Kolenc P, Mikolajczak R, Studen A, Simoncic U, Virgolini I, Trofimiuk-Muldner M, Garnuszek P, Rangger C, Fani M, Glowa B, Skorkiewicz K, Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging 2023 Nov;50(13):4110-4111. Epub 2023 Jul 15 doi: 10.1007/s00259-023-06335-9. PMID: 37452871Free PMC Article
Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy.
Naveed Ahmad JA, Schroeder BB, Ruhoy SM, Kennecke HF, Lin BS
Clin Nucl Med 2022 May 1;47(5):409-413. doi: 10.1097/RLU.0000000000004130. PMID: 35307721Free PMC Article
Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.
Zhuo ZG, Zhu YK, Deng HY, Li G, Luo J, Alai GH, Lin YD
J BUON 2019 Jan-Feb;24(1):368-373. PMID: 30941993
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J
Cancer Metastasis Rev 2013 Dec;32(3-4):465-77. doi: 10.1007/s10555-013-9421-0. PMID: 23589060

Prognosis

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E, Karaca H, Koca S, Sevinç A, Hacioğlu B, Özkan M, Özçelik M, Duran AO, Hacibekiroğlu İ, Yildiz Y, Tanriverdi Ö, Menekşe S, Aksoy A, Bozkurt O, Urvay S, Uysal M, Demir H, Çiltaş A, Dane F
Anticancer Drugs 2017 Feb;28(2):222-229. doi: 10.1097/CAD.0000000000000445. PMID: 27768606
Transplantation and Debulking Procedures for Neuroendocrine Tumors.
Frilling A, Al-Nahhas A, Clift AK
Front Horm Res 2015;44:164-76. Epub 2015 Aug 14 doi: 10.1159/000382145. PMID: 26303711
The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J
Cancer Metastasis Rev 2013 Dec;32(3-4):465-77. doi: 10.1007/s10555-013-9421-0. PMID: 23589060

Clinical prediction guides

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC
Ann Oncol 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193. PMID: 28444114Free PMC Article
Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.
Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH
Oncologist 2017 Feb;22(2):165-172. Epub 2017 Feb 8 doi: 10.1634/theoncologist.2016-0175. PMID: 28179574Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...